Neuronetics, Inc. STIM

Company Overview

Neuronetics, Inc. is a U.S.-based medical technology company focused on neurohealth therapies, primarily through non-invasive neuromodulation technologies used in psychiatry. The company operates in the healthcare and medical device industries and is best known for its NeuroStar Advanced Therapy platform, a transcranial magnetic stimulation (TMS) system cleared by the U.S. Food and Drug Administration for the treatment of major depressive disorder and certain other mental health conditions. Revenue is primarily generated through the sale and lease of NeuroStar systems, recurring treatment session revenues tied to treatment utilization, and sales of treatment accessories and service agreements.

Neuronetics primarily serves psychiatric practices, hospitals, behavioral health clinics, and mental health providers in the United States, with expanding international activity through distribution relationships. The company positions itself as a leader in the TMS market through clinical evidence, installed base scale, payer coverage expansion, and recurring revenue generated from treatment utilization. Founded in 2003 and headquartered in Malvern, Pennsylvania, the company evolved from an early-stage neuromodulation developer into a commercial-stage medical device business following FDA clearance of NeuroStar in 2008 and its subsequent public listing on Nasdaq under the ticker STIM in 2018.